Better in Delayed
BETTER IN THE DELAYED PHASE
POWERFUL PREVENTION OF DELAYED EMESIS1,3
-
The most commonly administered chemotherapy agents included cyclophosphamide
<1500 mg/m2, doxorubicin >25 mg/m2,
cisplatin
50 mg/m2, epirubicin, methotrexate
>250 mg/m2, and carboplatin.
IN SUBSET
-
Breast cancer patients (n=476):4
- ALOXI® resulted in a significantly better CR rate than ondansetron/dolansetron - in the
delayed phase of CINV (59% vs 40%, respectively; p<0.001).
-
Patients
65 years of age (n=165):5
- ALOXI resulted in a significantly better CR rate
than ondansetron/dolasetron
- in the delayed phase of CINV (72% vs 54%, respectively; p<0.025).
Prevention of both acute and delayed emesis in the first cycle leads to an even lower
probability (<10%) of delayed emesis in subsequent cycles.6
|
|
Click here to review the results of the ALOXI Phase III
Clinical Trial.
References
- Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol, 2003;14:1570-1577.
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
- Rubenstein EB, Gralla RJ, Eisenberg P, et al. Palonosetron (PALO) compared with Ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase II trials. Proc Am Soc Clin Oncol. 2003;22:729.
- Hudis CA, Hainsworth JD, Perez EA, Macciocchi A. Palonosetron (PALO) is more effective than ondansetron/dolansetron (OND/DOL) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer (BC); combined results from 2 phase III trials, Breast Cancer Res Treat. 2003;82(suppl 1):153. Abstract 635.
- Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients: results from tow randomized, controlled clinical trials. J Support Oncol 2005;3:369-374.
- The Italian Group for Antiemetic Research. Delayed emesis induced by moderately ememetogenic chemotherapy: do we need to treat all patients? Ann Oncol. 1997;8:561-567.
During initial and repeat courses of chemotherapy, ALOXI helps prevent and control nausea and vomiting the day following chemotherapy that is highly likely to cause nausea and vomiting, and for up to 5 days following chemotherapy that is likely to cause nausea and vomiting.
The most frequent side effects of ALOXI include headache and constipation. If you have or may develop significant heart rhythm changes, talk with your healthcare professional before receiving ALOXI.
ALOXI is available by prescription only. Please see the important product information for ALOXI for more information.
This site does not contain everything that is known about ALOXI. If you would like to know more, talk to your healthcare professional.